Is Bio Path Stock a Good Investment?
Bio Path Investment Advice | BPTH |
- Examine Bio Path's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bio Path's leadership team and their track record. Good management can help Bio Path navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Bio Path's business and its evolving consumer preferences.
- Compare Bio Path's performance and market position to its competitors. Analyze how Bio Path is positioned in terms of product offerings, innovation, and market share.
- Check if Bio Path pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bio Path's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bio Path Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bio Path Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Bio Path Stock
Researching Bio Path's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 0.71. The company recorded a loss per share of 8.34. Bio Path Holdings last dividend was issued on the 18th of January 2019. The entity had 1:20 split on the 23rd of February 2024.
To determine if Bio Path is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bio Path's research are outlined below:
| Bio Path Holdings generated a negative expected return over the last 90 days | |
| Bio Path Holdings has high historical volatility and very poor performance | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Bio-Path Holdings Inc Q3 2024 Earnings Call Highlights Strategic Advances and Financial ... |
Bio Path uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bio Path Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio Path's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bio Path's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bio Path's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-10 | 2021-09-30 | -0.33 | -0.29 | 0.04 | 12 | ||
2021-05-13 | 2021-03-31 | -0.49 | -0.43 | 0.06 | 12 | ||
2023-03-31 | 2022-12-31 | -0.45 | -0.52 | -0.07 | 15 | ||
2022-08-15 | 2022-06-30 | -0.49 | -0.42 | 0.07 | 14 | ||
2021-08-12 | 2021-06-30 | -0.39 | -0.26 | 0.13 | 33 | ||
2023-05-11 | 2023-03-31 | -0.45 | -0.66 | -0.21 | 46 | ||
2021-03-09 | 2020-12-31 | -0.78 | -0.57 | 0.21 | 26 | ||
2020-05-14 | 2020-03-31 | -0.67 | -0.9 | -0.23 | 34 |
Know Bio Path's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Path is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Path Holdings backward and forwards among themselves. Bio Path's institutional investor refers to the entity that pools money to purchase Bio Path's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 4.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 97 K | Hrt Financial Llc | 2024-06-30 | 14.1 K | Vanguard Group Inc | 2024-09-30 | 13.5 K | Geode Capital Management, Llc | 2024-06-30 | 10.9 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Blackrock Inc | 2024-06-30 | 2.4 K | Ubs Group Ag | 2024-06-30 | 859 | Qube Research & Technologies | 2024-06-30 | 100.0 |
Bio Path's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.44 M.Market Cap |
|
Bio Path's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.99) | (4.74) | |
| Return On Capital Employed | (12.06) | (11.45) | |
| Return On Assets | (4.99) | (4.74) | |
| Return On Equity | (36.46) | (34.64) |
Determining Bio Path's profitability involves analyzing its financial statements and using various financial metrics to determine if Bio Path is a good buy. For example, gross profit margin measures Bio Path's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bio Path's profitability and make more informed investment decisions.
Evaluate Bio Path's management efficiency
Bio Path Holdings has return on total asset (ROA) of (1.4003) % which means that it has lost $1.4003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6618) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -4.74. The Bio Path's current Return On Capital Employed is estimated to increase to -11.45. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.92 | 0.88 | |
| Tangible Book Value Per Share | 0.92 | 0.88 | |
| Enterprise Value Over EBITDA | (0.22) | (0.23) | |
| Price Book Value Ratio | 10.04 | 10.54 | |
| Enterprise Value Multiple | (0.22) | (0.23) | |
| Price Fair Value | 10.04 | 10.54 | |
| Enterprise Value | 2.1 M | 2 M |
Understanding the operational decisions made by Bio Path management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.222 |
Basic technical analysis of Bio Stock
As of the 22nd of November, Bio Path shows the Mean Deviation of 4.27, standard deviation of 7.01, and Risk Adjusted Performance of (0.07). Bio Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bio Path's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Path insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Path's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Path insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bio Path's Outstanding Corporate Bonds
Bio Path issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Path Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Path Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View |
Understand Bio Path's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bio Path's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 41.4 | |||
| Mean Deviation | 4.27 | |||
| Coefficient Of Variation | (964.61) | |||
| Standard Deviation | 7.01 | |||
| Variance | 49.13 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (1.65) | |||
| Treynor Ratio | 41.39 | |||
| Maximum Drawdown | 51.22 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 6.67 | |||
| Skewness | 2.77 | |||
| Kurtosis | 17.02 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 41.4 | |||
| Mean Deviation | 4.27 | |||
| Coefficient Of Variation | (964.61) | |||
| Standard Deviation | 7.01 | |||
| Variance | 49.13 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (1.65) | |||
| Treynor Ratio | 41.39 | |||
| Maximum Drawdown | 51.22 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 6.67 | |||
| Skewness | 2.77 | |||
| Kurtosis | 17.02 |
Consider Bio Path's intraday indicators
Bio Path intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bio Path stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 4711.59 | |||
| Daily Balance Of Power | 0.1667 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.81 | |||
| Day Typical Price | 0.81 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.02 |
Bio Stock media impact
Far too much social signal, news, headlines, and media speculation about Bio Path that are available to investors today. That information is available publicly through Bio media outlets and privately through word of mouth or via Bio internal channels. However, regardless of the origin, that massive amount of Bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bio Path news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bio Path relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bio Path's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bio Path alpha.
Bio Path Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bio Path can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
ACHR, BPTH, PLUG, REGRF:
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bio Path Corporate Management
| Michael MBA | VP Operations | Profile | |
| Alan MacKenzie | Consultant | Profile | |
| Thomas Walker | Consultant | Profile | |
| MBA Ashizawa | Development Research | Profile | |
| Peter MBA | Chairman, CoFounder | Profile | |
| Jeffery MD | Consultant | Profile | |
| Victoria Rac | Regulatory Consultant | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bio Path's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.